Oppenheimer Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has maintained an Outperform rating on IDEAYA Biosciences (NASDAQ:IDYA) and raised the price target from $30 to $35.
August 11, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has maintained an Outperform rating on IDEAYA Biosciences and raised the price target from $30 to $35, which could lead to a positive market reaction.
The raised price target by Oppenheimer indicates a positive outlook for IDEAYA Biosciences. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100